高级检索
当前位置: 首页 > 详情页

Development and validation of a predictive model based on clinical and MpMRI findings to reduce additional systematic prostate biopsy

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Sichuan Univ, Dept Radiol, West China Hosp, 37 Guoxue St, Chengdu 610041, Sichuan, Peoples R China [2]Sichuan Univ, Funct & Mol Imaging Key Lab Sichuan Prov, West China Hosp, Chengdu, Sichuan, Peoples R China [3]Sichuan Canc Hosp, Dept Ultrasound, Chengdu, Sichuan, Peoples R China [4]Sichuan Univ, Dept Ultrasound, West China Hosp, Chengdu, Sichuan, Peoples R China [5]Sichuan Univ, Dept Urol, West China Hosp, Chengdu, Sichuan, Peoples R China [6]Sanya Peoples Hosp, Dept Radiol, Sanya, Hainan, Peoples R China
出处:
ISSN:

关键词: Prostate cancer Magnetic resonance imaging Nomogram Biopsy

摘要:
ObjectivesTo develop and validate a predictive model based on clinical features and multiparametric magnetic resonance imaging (mpMRI) to reduce unnecessary systematic biopsies (SBs) in biopsy-naive patients with suspected prostate cancer (PCa).MethodsA total of 274 patients who underwent combined cognitive MRI-targeted biopsy (MRTB) with SB were retrospectively enrolled and temporally split into development (n = 201) and validation (n = 73) cohorts. Multivariable logistic regression analyses were used to determine independent predictors of clinically significant PCa (csPCa) on cognitive MRTB, and the clinical, MRI, and combined models were established respectively. Area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses were assessed.ResultsProstate imaging data and reporting system (PI-RADS) score, index lesion (IL) on the peripheral zone, age, and prostate-specific antigen density (PSAD) were independent predictors and included in the combined model. The combined model achieved the best discrimination (AUC 0.88) as compared to both the MRI model incorporated by PI-RADS score, IL level, and zone (AUC 0.86) and the clinical model incorporated by age and PSAD (AUC 0.70). The combined model also showed good calibration and enabled great net benefit. Applying the combined model as a reference for performing MRTB alone with a cutoff of 60% would reduce 43.8% of additional SB, while missing 2.9% csPCa.ConclusionsThe combined model based on clinical and mpMRI findings improved csPCa prediction and might be useful in making a decision about which patient could safely avoid unnecessary SB in addition to MRTB in biopsy-naive patients.Critical relevance statementThe combined model based on clinical and mpMRI findings improved csPCa prediction and might be useful in making a decision about which patient could safely avoid unnecessary SB in addition to MRTB in biopsy-naive patients.Key points center dot Age, PSAD, PI-RADS score, and peripheral index lesion were independent predictors of csPCa.center dot Risk models were used to predict the probability of detecting csPCa on cognitive MRTB.center dot The combined model might reduce 43.8% of unnecessary SBs, while missing 2.9% csPCa.Key points center dot Age, PSAD, PI-RADS score, and peripheral index lesion were independent predictors of csPCa.center dot Risk models were used to predict the probability of detecting csPCa on cognitive MRTB.center dot The combined model might reduce 43.8% of unnecessary SBs, while missing 2.9% csPCa.Key points center dot Age, PSAD, PI-RADS score, and peripheral index lesion were independent predictors of csPCa.center dot Risk models were used to predict the probability of detecting csPCa on cognitive MRTB.center dot The combined model might reduce 43.8% of unnecessary SBs, while missing 2.9% csPCa.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 核医学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 核医学
JCR分区:
出版当年[2023]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2023]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Sichuan Univ, Dept Radiol, West China Hosp, 37 Guoxue St, Chengdu 610041, Sichuan, Peoples R China [2]Sichuan Univ, Funct & Mol Imaging Key Lab Sichuan Prov, West China Hosp, Chengdu, Sichuan, Peoples R China
通讯作者:
通讯机构: [1]Sichuan Univ, Dept Radiol, West China Hosp, 37 Guoxue St, Chengdu 610041, Sichuan, Peoples R China [2]Sichuan Univ, Funct & Mol Imaging Key Lab Sichuan Prov, West China Hosp, Chengdu, Sichuan, Peoples R China [6]Sanya Peoples Hosp, Dept Radiol, Sanya, Hainan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naïve Men: A Meta-Analysis. [2]Transperineal 3-Core Magnetic Resonance Imaging Ultrasound Fusion Targeted Plus Laterally 6-Core Systematic Biopsy in Prostate Cancer Diagnosis [3]Transperineal Magnetic Resonance Imaging-Targeted Biopsy May Perform Better Than Transrectal Route in the Detection of Clinically Significant Prostate Cancer: Systematic Review and Meta-analysis. [4]Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies [5]Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis. [6]Application of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with magnetic resonance spectroscopy (MRS) in prostate cancer diagnosis [7]Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China [8]The Impact of Prostate Volume on Prostate Cancer Detection: Comparing Magnetic Resonance Imaging with Transrectal Ultrasound in Biopsy-naïve Men [9]Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis [10]Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml-1 to 10 ng ml-1

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号